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Trypanosomiasis has been recognized as a scourge in sub-Saharan Africa for centuries.
The disease, caused by protozoan parasites of the Trypanosoma genus, is a major
cause of mortality and morbidity in animals and man. Human African trypanosomiasis
(HAT), or sleeping sickness, results from infections with T. brucei (b.) gambiense
or T. b. rhodesiense with T. b. gambiense accounting for over 95% of infections.
Historically there have been major epidemics of the infection, followed by periods of
relative disease control. As a result of concerted disease surveillance and treatment
programmes, implemented over the last two decades, there has been a significant
reduction in the number of cases of human disease reported. However, the recent
identification of asymptomatic disease carriers gives cause for some concern. The
parasites evade the host immune system by switching their surface coat, comprised
of variable surface glycoprotein (VSG). In addition, they have evolved a variety of
strategies, including the production of serum resistance associated protein (SRA) and
T. b. gambiense-specific glycoprotein (TgsGP) to counter host defense molecules.
Infection with either disease variant results in an early haemolymphatic-stage followed
by a late encephalitic-stage when the parasites migrate into the CNS. The clinical
features of HAT are diverse and non-specific with early-stage symptoms common to
several infections endemic within sub-Saharan Africa which may result in a delayed
or mistaken diagnosis. Migration of the parasites into the CNS marks the onset of
late-stage disease. Diverse neurological manifestations can develop accompanied by
a neuroinflammatory response, comprised of astrocyte activation, and inflammatory
cell infiltration. However, the transition between the early and late-stage is insidious
and accurate disease staging, although crucial to optimize chemotherapy, remains
problematic with neurological symptoms and neuroinflammatory changes recorded in
early-stage infections. Further research is required to develop better diagnostic and
staging techniques as well as safer more efficacious drug regimens. Clearer information
is also required concerning disease pathogenesis, specifically regarding asymptomatic
carriers and the mechanisms employed by the trypanosomes to facilitate progression to
the CNS and precipitate late-stage disease. Without progress in these areas it may prove
difficult to maintain current control over this historically episodic disease.
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INTRODUCTION
Human African trypanosomiasis (HAT), also known a sleeping
sickness, is one of the world’s classical “neglected diseases.”
Transmitted by the bite of the blood-sucking tsetse fly of the
Glossina genus, HAT is caused by protozoan parasites of the
Trypanosoma genus (1–3). The incidence of HAT shows a
latitudinal gradient with reported cases occurring in sub-Saharan
regions between the latitudes 14◦ North and 29◦ South. It
has been estimated that about 60 million people throughout
36 African countries are at risk from developing the disease,
one which is usually, but not always, fatal if untreated or
inadequately treated (4). There are two clinical variants of HAT,
the West African form caused by Trypanosoma brucei gambiense
(abbreviated to T. b. gambiense) and the East African form
caused by T. b. rhodesiense parasites (5). The term “brucei”
reflects the pioneering work on the disease carried out by the
Scottish microbiologist Sir David Bruce in the last decade of
the nineteenth century when the links between the parasite,
the fly vector and wild and domestic animals were established
unambiguously (5). Although T. b. gambiense disease is more
common and causes about 95–97% of the reported HAT cases,
with T. b. rhodesiense cases constituting the other 3–5% of
reported cases, it has been estimated that the latter disease is
responsible for about 18% of the total risk of infection throughout
sub-Saharan Africa (6) as well as being the cause of 72% of cases
that occur in European and US travelers to endemic regions of
Africa for the primary purpose of visiting the African game parks
(7). Though much less common and widespread, the disease
caused by T. b. rhodesiense is a more acute and severe one
compared with that due to T. b. gambiense.
African trypanosomiasis is amajor cause of bothmortality and
morbidity in bothman and domestic livestock and there is a close
relationship between human and animal trypanosomiasis (also
known as nagana). The main reservoir of infective trypanosomes
in T. b. gambiense are other humans whereas domestic and wild
animals such as cattle are the main reservoir of infection for
HAT caused by T. b. rhodesiense (4) (though some animals can
also harbor T. b. gambiense). If domestic cattle are infected with
trypanosomiasis then they will be ineffective for food and milk
production with significant socio-economic consequences so the
animal disease and the human disease should not be considered
in isolation. The problem has been compounded by the failure to
reduce significantly the tsetse fly-infested regions of sub-Saharan
Africa over the last 100 years, an area that continues to be in the
region of a third of the land mass of the African continent (8).
EPIDEMIOLOGY
Since it was first recognized HAT has been characterized by
disease epidemics (especially in the early twentieth century),
periods when the disease has been kept under relative control,
particularly so in the 1960s, and also periodic disease resurgences
which have often been associated with wars. When estimating
the incidence of new HAT cases at different times there has
always been the problem of under-diagnosis and/or under-
reporting so one may only be detecting the “tip of the iceberg.”
However, despite these caveats, it is clear that there has been
a steady and indeed significant decline in new cases of HAT
over the last 10–20 years. This is the consequence of massive
and concerted collaborative efforts to control the disease by
WHO, non-government organizations, African governments, the
pharmaceutical industry, and research charities and Institutions.
The key measures that have allowed this achievement have been
to detect, isolate, and treat human HAT cases to prevent disease
spread and also to provide more effective vector control. There
was a large increase in HAT cases in the 1980s which continued
for over a decade and WHO estimated in 1998 that there were
about 300,000 new cases per year in Africa (5, 9). But by 2006
WHOestimated that this high figure had been reduced to 50,000–
70,000 cases (4, 10). By 2009 WHO estimated that the number of
new cases per year had been reduced to below 10,000 for the first
time (9,878 cases), and in 2014 only 3,796 cases were reported
with <15,000 estimated cases (3, 11). By 2016 the reported
number had been further reduced to 2,184 cases. In all these
reports the majority of cases were due to T. b. gambiense, and
there has been a relatively greater reduction in the number of
these cases compared to T. b. rhodesiense. While most reported
cases of HAT due to T. b. gambiense are to be found in the
Democratic Republic of Congo (DRC), most of the reported cases
of T. b. rhodesiense disease are found in Uganda and Malawi (3).
However, in Uganda both variants of HAT have been detected (4)
with the prospect of some patients being co-infected with the two
diseases which raises important potential issues in diagnosis and
treatment.
Interestingly, the number of documented HAT cases in the
DRC in 2007 was actually slightly more than twice the number
of cases reported to WHO (12), so a degree of caution should
be exercised in interpreting the incidence figures. However, it is
abundantly clear that these concerted control efforts have been
very successful in reducing the incidence of HAT. It should also
be emphasized that HAT continues to pose a serious potential risk
to travelers to sub-Saharan Africa (East or West) with most cases
due to T. b. rhodesiense, and 94 HAT cases were reported in non-
endemic countries between 2000 and 2010 (7). The likely reason
for this is that many European and US travelers to Africa visit the
game reserves which are mainly located in East Africa, where T.
b. rhodesiense is commonly found in wildlife reservoirs.
BIOLOGICAL CONSIDERATIONS
Some essential features of the interactions between the
trypanosome parasite and the animal or human host are given
here in brief, but these have been described in detail elsewhere
(3, 4). The trypanosome is a unicellular protozoan parasite, and
10% of its 9,000 genes code for variant surface glycoproteins
(VSG). These proteins are distributed over the surface of the
trypanosome and play a major role in determining its immune
specificity. The VSG are attached to the trypanosome’s outer
membrane by glycosylphosphatidylinositol anchors. During
infection of the host a constant low frequency gene conversion
process occurs which switches the VSG genes in and out of
the expression site. As a result there is a continuous process of
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antigenic variation which enables the trypanosome to constantly
evade the host’s immune responses which would otherwise have
the ability to destroy the parasite. This phenomenon of antigenic
variation, which is also shown by some other pathogens, explains
why vaccination against the trypanosome infection has hitherto
proved to be unfeasible (4, 8).
Humans have evolved innate defenses against some
trypanosome species. There are proteins present in human serum
which are capable of producing lysis of animal trypanosomes,
called trypanolytic factors. These factors are comprised of
apolipoprotein A1 (APOA1), apolipoprotein L1 (APOL1), and
haptoglobin related protein (HPR) contained within two serum
protein complexes, trypanosome lytic factor 1 and 2 (TLF-1
and TLF-2) (13). However, the two trypanosome species which
infect humans, that is, T. b. rhodesiense and T. b. gambiense, have
evolved mechanisms to overcome this lytic resistance factor. In
the case of T. b. rhodesiense the parasite contains the SRA gene
which encodes the serum resistance associated protein (SRA)
which is able to bind to TLF, thereby conferring resistance to
lysis. The mechanism of overcoming TLF-induced lysis used by
T. b. gambiense, which lacks the SRA gene, is somewhat different
and more complex, involving a reduction in binding affinity
of the parasite receptor for TLF, the involvement of a mutated
form of VSG known as T. b. gambiense-specific glycoprotein
(TgsGP) and increased production of cysteine proteases that
degrade APOL1 (13). It has also been shown recently that
different APOL1 gene variants, known as G1 and G2, which
are associated with a recessive kidney diseases risk, affect an
individual’s susceptibility to HAT, resulting in the positive
selection of certain variants in sub-Saharan Africa (14). Thus, G2
was associated with a protective effect against T. b. rhodesiense
and a faster progression of T. b. gambiense disease, whereas G1
was associated with asymptomatic but infected individuals and
the failure to detect trypanosomes (14).
The detailed lifecycle of the parasite has been described
comprehensively elsewhere (3, 5). Starting at the point where the
tsetse fly bites an infected individual or animal, the fly ingests
a “blood meal” which also contains trypanosomes. When the
latter enter the fly’s midgut they undergo a series of biochemical,
anatomical and pharmacological changes, and multiply prior to
moving to the salivary glands where the now infective parasites
are concentrated. The cycle is continued when the tsetse fly
then bites a human or animal host. During the first, early, or
“haemolymphatic stage” of infection the parasites multiply by
binary fission and spread throughout the bloodstream, lymphatic
system and lymph nodes, and also the systemic organs including
the liver, spleen, heart, endocrine organs, and visual system (15).
A chancre, which is the primary skin lesion, may or may not
appear at the site of the tsetse fly bite. When the trypanosomes
traverse the blood-brain barrier (BBB) to enter the central
nervous system (CNS), a process which usually occurs after a
few weeks in the case of T. b. rhodesiense and a few or several
months in the case of T. b. gambiense disease, this marks the
start of the second, late, or “encephalitic stage” of the disease.
This stage is characterized by a number of neurological features
(see below) and the CNS pathology shows a meningoencephalitis
with a typical inflammatory infiltrate, perivascular cuffing, and
cells called Morular or Mott cells which are typical of HAT and
consist of plasma cells containing aberrant Ig (15). The tempo
and overall duration of disease progression is different in the two
disease variants, with T. b. rhodesiense typically causing an acute
disease which, if untreated, is likely to kill the patient in a few
weeks whereas the disease caused by T. b. gambiense is typically
a more chronic disease which can last for many months and
indeed sometimes even longer for years. The reasons for these
pathological, and therefore clinical, differences between the two
variants is not known for certain though it may possibly reflect
a longstanding evolutionary adaptation of T. b. gambiense to the
human or animal host.
CLINICAL FEATURES
The diverse clinical features of early and late- stage HAT broadly
reflect the underlying pathology of the disease, except that,
unlike the pathological features, there are no clinical criteria
that can reliably distinguish or predict the onset of the early
and late clinical stages which tend to run in to each other
seamlessly (5). Although there are numerous clinical features
that are typical of many cases of early and late- stage HAT, it
should be appreciated that these may vary considerably. Thus,
there are marked clinical phenotypic differences seen between
the two variants of HAT, between travelers from non-endemic
countries and patients residing in Africa, between patients in
different geographical regions of one African country, and also
between patients living in different African countries. Despite the
relatively recent recognition of the clinical heterogeneity of HAT,
it is still possible to list the commonly observed symptoms and
signs.
Early-stage symptoms may be vague and non-specific which
may delay the clinical suspicion and diagnosis. Thus, such
features as lassitude, intermittent fever, arthralgia, and headache
may initially predominate raising the possibility of malaria
which may of course co-exist in patients with HAT (1). As
the parasites spread within the bloodstream and lymphatic
system corresponding systemic features may then follow. Such
patients in endemic areas may therefore show evidence of
lymphadenopathy (especially in the posterior cervical region
in the case of T. b. gambiense disease which is known as
Winterbottom’s sign), haemolytic anemia, hepatomegaly and
abnormal liver function, splenomegaly, endocrine disturbances,
cardiac involvement such as pericarditis and congestive cardiac
failure as well as ophthalmic involvement (1, 15). The clinical
presentation in travelers from non-endemic countries who are
infected has been reported to be somewhat different and atypical
as they present with mainly gastro-intestinal symptoms such as
diarrhea and jaundice in association with an acute febrile illness
(16), and lymphadenopathy is rare in these latter individuals.
The reason(s) for the clinical differences in the presentation
of HAT in these various populations are as yet unclear and
studies investigating possible genetic influences are on-going.
The relatively low numbers of white travelers infected with
HAT may also be a factor in accurately determining variations
in disease presentation. It has been recognized recently that
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neurological symptoms and signs may be seen in early-stage
disease which is somewhat counter-intuitive but may reflect
underlying pathogenetic mechanisms. Thus, it was found that
the clinical profiles of HAT may be focus-specific in that
cranial nerve palsies, urinary incontinence, somnolence, tremor,
and abnormal gait were detected in some patients with early
stage T. b. rhodesiense disease in two distinct regions of
Uganda (17). Further, a retrospective study of patients in a
hospital in Uganda found that 26.7 and 6.7% of the early
stage T. b. rhodesiense patients presented with late stage signs
of sleep disorder and mental confusion, respectively (18). The
pathogenetic significance of these interesting observations has
yet to be elucidated but they do indicate the great importance of
accurate and objective methods of disease staging.
Once the parasites have crossed the BBB to enter the CNS,
the late or encephalitic stage of HAT is initiated with a wide
variety of neurological symptoms and signs being potentially
manifest. The progression and duration of the disease and the
neurological disability is faster in T. b. rhodesiense compared
to T. b. gambiense disease. Neurological features referable to
most parts of the nervous system have been described though
some are more typical. A characteristic sleep disorder with
daytime somnolence and nocturnal insomnia is common in
both types of HAT in endemic areas (and indeed gives the
disease its name) with one large prospective study reporting
its incidence in 74.4% out of a total of 2,541 patients (19).
However, sleep disturbances occur only rarely in travelers
with HAT (16). Initially in the late-stage there may be non-
specific symptoms such as irritability, lassitude, psychiatric, and
behavioral disturbances which may obscure the actual diagnosis
and/or suggest alternative diagnoses. A wide variety of motor
symptoms and signs may occur involving the pyramidal or
extrapyramidal systems with involuntary movements including
tremors, slurred speech, headache, myelopathy, myositis, and
cerebellar ataxia (1). Sensory involvement is also well recognized
such as sensory symptoms and motor neuropathy. A variety of
visual features may also occur such as optic neuritis, diplopia and
local eye complications such as iritis, keratitis, and conjunctivitis
(1). If untreated the patient will deteriorate inexorably with
progressive impairment of consciousness, incontinence, seizures,
and eventually death in most cases.
The geographical differences in the clinical manifestations of
HAT are also notable. Related to this, the severity and speed
progression of late stage disease in T. b. rhodesiense patients can
also be genetically determined in that genetically distinct parasite
genotype variants have been reported as being associated with
these two clinical aspects in geographically separated regions of
Uganda (20). The clinical features of HAT can differ even in
different regions of the same country as evidenced by a study (17)
which found that the phenotype of T. b. rhodesiense differed in
the spatially separated areas of Soroti and Tororo in the country
of Uganda. In the former region neurological involvement was
apparent earlier and the transition from the early to the late-
stage was faster than in the latter region, though neurological
dysfunction was more severe in Tororo. Phenotypic differences
in T. b. rhodesiense cases can also vary in different countries as
evidenced by a study of 138 patients with late stage disease (21)
which found that typical HAT-specific neurological features were
frequently observed in patients in Tanzania compared to those
in Uganda where the neurological features in the late-stage were
more non-specific such as fever, headache, general body pain, and
joint pains.
It has been known for several years that a few patients with
evidence of T. b. gambiense HAT infection survive and are
asymptomatic without treatment. This has been confirmed in
some detail over the last decade and shows that HAT is not
always a fatal illness which is effectively a significant change in the
established disease paradigm. This type of phenomenon is well
recognized in certain breeds of African cattle such as the Ndama
and West African Shorthorn which are “trypanotolerant” due
their genetic ability to resist both the anemia and parasitaemia
normally induced by trypanosomal infection (8). While some
West African patients with T. b. gambiense HAT, who had
declined treatment, are able to be “resistant” to infection in
that they continue to be asymptomatic, aparasitaemic, and also
seronegative, others are also asymptomatic and aparasitaemic
following an established infection but continue to be seropositive
and might be regarded as slightly different and therefore
“tolerant” of infection (22–24). An intriguing and important
question is just how frequent these phenomena are as the answer
to this is unknown at present. It is also unclear whether such
tolerant individuals represent a potential source of infection
to others and whether they should be treated when detected.
Furthermore, there have been reports of a few patients with
T. b. gambiense disease who have survived for many years
without treatment, and indeed a recent report described the
case of a man who presented with HAT at least 29 years after
infection (25) which is the longest duration of HAT infection ever
reported. Of possible relevance to such observations is the recent
discovery that the skin is a significant and hitherto overlooked
reservoir for vector-borne African trypanosomes (26). This
very important study detected the presence of extravascular
trypanosomes in human skin biopsies in undiagnosed individuals
who were aparasitaemic. Further, the authors showed that
substantial quantities of trypanosomes existed within the skin
following experimental animal (mouse) infection, which could be
transmitted to the tsetse vector. These findings raise major issues
not only in terms of current diagnostic methods (see below) but
also for strategies that are being devised for eventual control and
eradication of HAT (26).
NEUROPATHOGENESIS OF HAT
The routes and mechanisms employed by the parasite to enter
and persist within the CNS remain an area of much debate.
In vitro blood-brain barrier (BBB) models have shown that
trypanosomes can cross a human brainmicrovascular endothelial
cell layer producing only a transitory reduction in barrier
integrity (27). Further studies suggest that both parasite and host
enzymes, together with induction of calcium signaling pathways
at the endothelial cell layer, could be fundamental in the ability of
trypanosomes to circumvent the BBB and gain entry to the CNS
(28, 29). The effect of trypanosome infection on BBB function
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has also been investigated in rodent models of the disease
(30–32). Studies tracing intravenously injected fluorescent dyes
in trypanosome infected rats found increasing penetration of
the brain parenchyma as the infection advanced through the
later stages (30) suggesting a progressive deterioration in BBB
function. This dysfunction was also seen in murine infections
when BBB integrity was monitored using contrast-enhanced
MRI, however in this case, leakage of contrast agent was
detected prior to the onset of late-stage disease and increased
as the infection progressed (31, 32). This early and progressive
development of BBB impairment has also been seen in human
cases of T. b. rhodesiense infection. Using the CSF/serum albumin
quotient as ameasure of BBB function, a deterioration in integrity
was detected in 6% of patients presenting in early-stage disease
and increased to 42% of patients in the encephalitic stage (33).
Animal models of HAT have facilitated in depth investigations
of disease progression and parasites have been found within
the brain tissue using this controlled approach. Trypanosomes
have been detected in the neuropil in both primate (34) and
rodent (30, 35–38) models of late-stage infections and more
recent studies, employing confocal microscopy to image labeled
parasites, suggest that trypanosomes invade the CNS very quickly
following infection (39, 40). Whether these parasites gain entry
to the brain via the CSF or by a haematogenous route remains
equivocal. Studies by Mogk et al. (41, 42) and Wolburg et al.
(43) suggest that the parasites may initially cross the fenestrated
vessels in the choroid plexus (Figure 1) to access the stroma
before traversing the blood-CSF-barrier and disseminate with
the CSF through the ventricles to the cisterna manga and sub-
arachnoid space from where they can populate the pia mater.
However, in these studies the parasites failed to enter the neuropil
from the pia mater. Paradoxically, CSF seems to prove a hostile
environment for trypanosomes. In vitro studies have shown that
the parasites will only survive for 20 h in CSF and that survival
time is further reduced if CSF from late-stage HAT patients is
employed in the culture medium (44). The unfavorable nature of
CSF has been purported as the cause of parasite migration from
the sub-arachnoid space into the pial cell layer (42). Fenestrated
vessels are also present within the circumventricular organs
(Figure 1) and trypanosomes have been shown to occupy these
regions in addition to the choroid plexus early after infection
(45, 46). However, the circumventricular organs are isolated
from other brain regions by another barrier system formed by
tanycytes and this cell layer would restrict further passage of
trypanosomes into the brain parenchyma (45). Recent studies
have captured images of parasites entering the neuropil directly
from the blood vessels (40) providing further evidence to suggest
that trypanosomes have the ability to traverse the BBB in vivo. In
human infections parasites have very rarely been detected within
the brain parenchyma on post-mortemmicroscopic examination
(47) although they are more often found within the cerebral
blood vessels (47–49). This is perhaps to be expected since
trypanosomes would deteriorate very quickly following death
of the host and many of the cases examined had been treated
with trypanocidal drugs (49, 50). Therefore, the exact route
and molecular mechanisms facilitating trypanosome traversal
into the brain parenchyma remain to be elucidated although
a combination of all three pathways seem the most probable
scenario (Figure 1).
The availability of genetically modified organisms has revealed
several important factors in trypanosome-CNS invasion and
the generation of the associated neuroinflammatory reaction.
These include factors involved in both the innate and adaptive
immune response. Innate immune response pathways involving
Toll-like receptor (TLR) 2- and TLR9—MyD88 signaling can
stimulate the expression of pro-inflammatory molecules such
as TNF-α and IFN α/β. By utilizing a series of TLR 2−/−,
TLR 9−/−, and MyD88−/− mice Amin et al. demonstrated
a reduction in leucocyte and parasite transmigration into the
CNS in the knockout animals that appeared to correlate with
reduced transcription of TNF-α and IFN-α/β (51). Additional
inflammatory mediators including IFN-γ (52, 53) and CXCL10
(53) have been shown to play a vital role in this invasion
process with trypanosomes and T-cells being confined between
the endothelial and parenchymal basements membranes of the
cerebral post-capillary vessels in IFN-γ−/− mice (52). The
laminin subtype present within the basement membrane also
influences the ability of trypanosomes and T-cells to enter the
CNS with regions containing laminin α4 being permissive to
transmigration while areas composed of laminin α5 deterred
traversal (52). Treatment of trypanosome infected mice with
minocycline, an antibiotic known to reduce the passage of T-cells
into the CNS in experimental allergic encephalomyelitis (EAE),
provided further evidence supporting a relationship between
lymphocyte crossing of the BBB and parasite brain invasion (54).
In this study reductions in the number of both CD45+ cells and
parasites were seen following drug administration together with
a significant inhibition in the transcription of intercellular cell
adhesion molecule-1 (ICAM-1) and E-selectin (54).
Animal models have also been essential in monitoring
the effect of trypanosome infection on the expression of
inflammatory mediators in the CNS, the balance of which
could be crucial to the outcome of the disease. An association
between high CNS concentrations of IFN-γ and TNF-α and a
more severe neuroinflammatory response has been demonstrated
while higher levels IL-10 and IL-6 were allied with mild CNS
inflammation (55). In agreement with these findings reduced
concentrations of plasma IFN-γ and TNF-α, lowered CNS
parasite burden and reduced neuropathology together with an
improved clinical presentation were seen following systemic
IL-10 administration in trypanosome infected mice (56). The
reduction in plasma IFN-γ and concomitant reduction in CNS
parasitosis and neuroinflammatory reaction is an interesting
finding due to the crucial role, described earlier, that INF-γ
appears to have on lymphocyte and trypanosome brain invasion.
DIAGNOSIS OF INFECTION AND DISEASE
STAGING
It is important to establish a positive diagnosis of HAT as soon as
possible after suggestive symptoms have started especially in view
of the toxic nature of current drug treatment and the dangers
of leaving the disease untreated. A high index of suspicion
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FIGURE 1 | Following infection trypanosomes spread via the haemolymphatic system to invade the peripheral organs. The infection precipitates an array of
non-specific symptoms mostly linked to the systemic immune reaction. When the disease progresses from the early to the late-stage the trypanosomes enter and
establish within the CNS. The routes exploited by the parasites to invade the CNS remain a topic of debate. The three main possibilities are highlighted. In each case
the parasites must circumvent a potential barrier (listed in red text) to gain entry to the neuropil. It is likely that a combination of these pathways is utilized. Progression
to late-stage induces a series of neuroinflammatory changes in the brain characterized by a pronounced astrocyte activation and lymphocyte infiltration. As the
disease advances, progressive deterioration in blood-brain barrier (BBB) function has been noted following systemic injection of fluorescent dyes and contrast
enhanced magnetic resonance imaging.
would be present if such an individual with typical symptoms
is known to have been bitten by a tsetse fly in an endemic
region of sub-Saharan Africa. Trypanosome parasites may be
visualized on a thin or thick peripheral blood smear which is
usually possible in the case of T. b. rhodesiense disease because of
the typically high blood parasite levels in such individuals (57).
By contrast, the cyclical parasitaemia with only intermittently
high blood parasite levels typically seen in T. b. gambiense often
makes direct demonstration of the parasite less likely though
this should still be looked for carefully. A greater adaptation
of T. b. gambiense to the host is thought to account for this
difference so a positive diagnosis for this variant usually needs
to be made by serological methods which themselves may be
problematic. The Card Agglutination Test for Trypanosomiasis
(CATT) has been used extensively for disease screening and is
of considerable use in regions where there is a high prevalence
of disease (2, 4), but it has a high incidence of false positive
results whichmakes it particularly problematic in areas where the
disease prevalence is low. A “false” positive occurs in a case that
cannot be confirmed by the presence of active blood paraesitemia.
The test also requires an electricity supply which may be difficult
in the African field. While some advanced molecular techniques
such as the Polymerase Chain Reaction (PCR) have been tested in
HAT there have been significant technical issues with these and
they would also not be very practical under field conditions (4).
Not surprisingly, much effort has been made recently into
developing alternative and more effective tests to diagnose HAT.
The development of what are now called Rapid Diagnostic
Tests (RDTs) is promising to transform our ability to make
this diagnosis for T. b. gambiense cases that require serological
methods of detection. A prototype rapid diagnostic test called
SD BIOLINE HAT has been developed (58) and was shown in
a multi-centric prospective non-inferiority study to recognize
two trypanosome antigens (VSG LiTat 1.3 and VSG LiTat 1.5),
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and its high sensitivity and specificity for HAT indicated its
ability to become an alternative screening method to the CATT;
it also does not require electrical instruments. It should be
emphasized, however, that both CATT and SD BIOLINE HAT
detect antibodies produced in response to identical VSG antigens,
so from an immunological point of view, the two tests measure
the same “event” using exactly the same immunological concept,
but with a different readout. It should also be appreciated that
although both assays have a very good negative predictive value,
and all patients that require treatment are detected, they score
relatively poorly in finding “true” active infections. For example,
repeated bites by T. b. brucei infected flies will induce an anti-
trypanosome response in the human host, but will not establish
an infection, and even a bite by a T. b. gambiense infected
fly could induce an immune response but may not necessarily
result in infection. A follow-up study showed that a recombinant
antigen-based RDT was as specific as, but more sensitive than,
the SD BIOLINE HAT, and was as sensitive as but slightly less
specific than the CATT (59). This suggested that the use of more
than one screening test for HAT might be optimal. Further, it
was shown recently that some RDTs that detect T. b. gambiense
disease in humans also cross-react with antibodies found in cattle
(60), findings that indicate that they may possibly be useful in
some studies of animal trypanosomiasis. Demonstrating the final
elimination of the disease may also be challenging when relying
on diagnostic tests that are based on the detection of a host
antibody response. Since the antibody response can remain viable
for a considerable period after the initial antigen encounter, these
test will not distinguish between patients exhibiting an active
infection and those that have been successfully treated and then
re-exposed to the VSG, through non-productive infected tsetse
bites, thereby boosting the antibody response. This could lead
to a scenario where passed exposure to HAT would be detected
rather than on-going infections masking the true incidence of the
disease.
Accurate and reliablemethods of disease staging to distinguish
the early from the late stages of HAT are extremely important
both because it is not possible to stage the disease on clinical
grounds alone, and also because the drug treatment for late-
stage disease is so toxic (see below). However, attempts to define
the late- stage on objective criteria have been controversial and
problematic in some cases. The currently accepted method of
identifying the late stage of both types of HAT when the CNS
has been invaded is the examination of the Cerebrospinal Fluid
(CSF) by lumbar puncture. The WHO criteria for defining late-
stage disease is more than 5 White Blood Cells (WBC)/mm3 or
the presence of trypanosomes in the CSF or both (9), though
a higher WBC cut off point such as 20 WBC//mm3 is used by
some physicians and investigators, especially in West Africa. A
major problem may arise in the case, for example, of a patient
with 6 WBC/mm3 in the CSF who may not in fact have CNS
disease but who nevertheless using the WHO criteria would
be treated with toxic late stage drugs. There is no universal
consensus as to either the biological definition of late-stage
disease or indeed the CSF criteria that are used to determine
late stage treatment (5). Attempts to circumvent this staging
problem using appropriate biomarkers of CNS disease have
been made and have included, for example, levels of CSF IgM
(61), neopterin (62), and combined panels of chemokines and
proteins (63), but the central problem with this approach is
that the results are compared with the WHO criteria which are
themselves controversial and not a “gold standard.” This is the
“circular argument” problem that investigators in this field have
to contend with. A recent analysis of this issue has suggested
a novel “reverse” approach in which statistical methods could
be used to test the performance of combinations of established
laboratory variables as staging biomarkers to correlate with the
CSF WBC/trypanosomes and clinical features of HAT (64). It is
hoped that in this way a particular CSF WBC can be identified
as giving a more reliable indication of CNS involvement in HAT,
thereby establishing the CSF WBC diagnosis on a firmer footing.
Though non-invasive methods to identify CNS stage disease have
been investigated such as polysomnography to detect alterations
of sleep structure in late- stage HAT (65), and also actigraphy to
measure body activity and sleep/wake cycles (66), at the current
stage of development these useful diagnostic adjuncts are more
likely to be used to detect disease relapses after treatment rather
than serve as primary indicators to serve as a firm basis for
initiating late stage treatment when it is first administered. This
disease staging issue would, of course, assume less importance if
an effective and non-toxic treatment for late-stage disease were to
become available.
CURRENT TREATMENT OF HAT
Current pharmacological therapy for HAT relies on just
a few drugs all of which were developed many years
ago and have a degree of toxicity which is most severe
in the case of drugs for late-stage disease. This subject
has been described in detail elsewhere (4, 15), and some
essential aspects and also recent therapeutic developments
are given here. It is only relatively recently that the
pharmaceutical agency, working with non-government
organizations and various academic researchers and
Institutions, has focused on developing new drugs for late-stage
HAT.
Drug treatment for early-stage disease for both HAT variants
is effective and less toxic than that for late-stage disease (3,
4). For early-stage T. b. gambiense drug therapy consists of
intramuscular (preferable) or intravenous or pentamidine. This
drug (which can also be given as second-line treatment of T. b.
rhodesiense) has reported side-effects that include hypotension,
abnormalities of glucose metabolism, renal dysfunction, and
gastro-intestinal symptoms (15). Treatment for the early-stage
of T. b. rhodesiense is with intravenous suramin (which can
also be given as second-line treatment of T. b. gambiense) and,
though effective, has the potential side-effects of mild renal
dysfunction, peripheral neuropathy, anaphylactic reactions, and
bone marrow toxicity resulting in peripheral blood abnormalities
(1, 5).
Drug treatment for late-stage disease in both variants is more
problematic. The only treatment currently available to treat late-
stage T. b. rhodesiense HAT is intravenous melarsoprol which
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was first used in 1949. Though every effective, melarsoprol is
painful to administer and is very toxic, with a fatality rate
of about 5–9% due in main part to a severe post-treatment
reactive encephalopathy (PTRE) which develops in 5–10% of
cases about half of whom die (3, 4). The actual cause of the
encephalopathy is unknown but may relate to the toxic effects
of massive and rapid parasite killing with a resultant cytokine
“storm.” The PTRE is characterized by coma, seizures, and
cerebral oedema which is usually treated with corticosteroids,
anticonvulsants, and intensive support. Other complications
of melarsoprol include peripheral neuropathy, skin rashes,
cardiotoxicity, and agranulocytosis (4, 15). Although an abridged
10 day intravenous melarsoprol treatment schedule is now
standard, the mortality rate of this regime still remains in
the region of 5.9% (67). Though also effective against late-
stage T. b. gambiense, melarsoprol is now second line therapy
for this variant. First-line therapy for T. b. gambiense is now
NECT (nifurtimox-eflornithine combination therapy) which is
a combined course of intravenous eflornithine (DFMO) (an
ornithine decarboxylase inhibitor) and oral nifurtimox (68).
NECT is less toxic than melarsoprol and is equally if not more
effective and for several years has been the initial therapy of
choice for this variant. However, NECT is not effective against
T. b. rhodesiense. While eflornithine monotherapy has also been
given for T. b. gambiense this is more toxic and less well tolerated
than NECT (3), so is not usually given. Potential side-effects
of eflornithine include alopecia, bone marrow toxicity, gastro-
intestinal features, and seizures. Whether drug resistance to
eflornithine may develop in the future is possible but remains to
be seen.
There are several new drugs for late-stage HAT in the
pipeline, in development or under evaluation. A drug of the
nitroheterocyclic group called fexinidazole is the focus of much
current interest. A recently published study reported that in a
phase 2/3 randomized non-inferiority trial of oral fexinidazole
vs. NECT therapy, in late-stage T. b. gambiense HAT in the
DRC and Central African Republic, oral fexinidazole successfully
treated 91% of patients at the 18 month assessment point
compared with a 98% treatment success rate with NECT, and
the treatment-related side effects were similar in both groups
(69). This is clearly a significant advance though the efficacy
of fexinidazole was less than that of NECT, and it remains to
be seen whether this drug is also effective in late-stage T. b.
rhodesiense disease. An effective oral drug has a number of
advantages, but at the current time both of the current authors
(PGK and JR) would still opt for NECT as first-line therapy
in the unfortunate event that they developed late-stage HAT.
Another promising drug currently under evaluation is a new
oral compound of the oxaborole group. This drug, called SCYX-
7158 cures CNS-stage HAT in an experimental mouse model
(70), was safe in a phase 1 trial, and is currently undergoing
evaluation in a phase 2/3 trial. Another very different approach
has been to develop a form of melarsoprol that can be given
orally but which retains its ability to be effective against HAT
while losing its toxicity. Complexed melarsorpol is formed by
inserting melarsoprol inside a cyclodextrin molecule to form
a fusion drug consisting of cyclodextrin-melarsoprol inclusion
complexes (71). This drug cured trypanosome infections when
given orally in a reproducible mouse model of HAT and was free
of toxic effects. The drug has dual European Medicines Agency
(EMA)/US Food and Drug Administration (FDA) approval as an
orphan drug for African trypanosomiasis and the EMA scientific
protocol advisory committee has approved a protocol for a phase
2 trial in T. b. rhodesiense HAT and it is hoped that such
a trial will be conducted when appropriate funding becomes
available.
PROSPECTS FOR EVENTUAL CONTROL
OF HAT
While it would clearly be ideal to eliminate HAT completely
from the whole of sub-Saharan Africa, the more realistic goals
of WHO are to eliminate sleeping sickness as a public health
problem by 2020 and to achieve interruption of its transmission
by 2030. These goals could be achievable, though there are several
challenges and caveats that should be taken into account.
HAT has frequently showed its ability to resurge even after
it had appeared to have been brought under control as was
the case, noted above, in the 1960s. This indicates that it may
prove to be a formidable task to realize both the WHO goals
in time. Related to this, it will be necessary for all the relevant
Institutions and agencies concerned to keep a very careful watch
over the changing prevalence of HAT and never to relax the
constantmonitoring of infected individuals so they can be treated
promptly. Some cases may reside in remote regions of sub-
Saharan Africa which poses a problem for effective screening
and may cause underestimates of infection to be made. War
poses a particular problem in this regard because of the inevitable
breakdown of social structures and difficulties in identifying
infected individuals. The problem may be compounded by the
difficulties in identifying patients in the early stage of disease
because the early symptoms are frequently non-specific. Further,
the fact that cattle are the animal reservoirs of infection for T.
b. rhodesiense disease will make it very difficult, and perhaps
impossible, to achieve complete control of this HAT variant.
Mass culling of domestic and wild animals is not a realistic
proposition, but the fact that this variant only causes a minority
of HAT cases, despite its severity and propensity to affectWestern
travelers, may possibly mitigate in part this issue. The prospects
for eventual control of animal trypanosomiasis will also be
limited, and the control and even elimination of the tsetse fly
vector for both the animal and human disease in all but a few
regions also seems unlikely especially when one considers how
little of the areas infested by the tsetse fly have diminished
over the last 100 years. Another significant issue is that the
true frequency of “asymptomatic” infected individuals is not
currently known. If such individuals are not identified by mass
screening they could potentially be a source of infection with
T. b. gambiense HAT, and this could hamper control efforts.
Further, the recent identification of the skin and extravascular
tissues in asymptomatic humans as a reservoir of trypanosomes
could also impair efforts to achieve the elimination of HAT as
a public health problem, especially if such individuals prove
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to be a source of infection to other people. There is also no
guarantee that current drugs will be able to reach and kill
the parasites in these previously unrecognized areas of the
body. Finally, there remains the underlying concern that drug
resistance may develop against both currently used and future
drugs especially if they are given by the oral route. While it is
hoped that the WHO aims are achieved within the intended
time frame, at least for T. b. gambiense HAT, it is clear that
there will be several significant obstacles that will need to be
overcome.
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